Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022
Epidemiology, Clinical Characteristics, and Diagnostic Testing Practices for Pneumocystis Pneumonia–Associated Hospitalizations, United States, 2019–2022.
Association between thromboembolic events and COVID-19 infection within 30 days: a case–control study among a large sample of adult hospitalized patients in the United States, March 2020–June 2021
Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study
Hospitalizations for Unspecified Mycoses in a Large Administrative Data Set and Implications for Fungal Disease Burden Estimates, United States, 2019–2021.
Vital Signs : Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections — United States
Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
